Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Wei-Chih Chen, Abraham S Kanate, Michael Craig, William P Petros & Lori A Hazlehurst. (2017) Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research 9, pages 307-314.
Read now
Read now
Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane$suffix/text()$suffix/text(), Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen & Kerry S. Campbell. (2017) The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms. OncoImmunology 6:9.
Read now
Read now
Sonja Genadieva Stavric, Francesca Bonello, Sara Bringhen, Mario Boccadoro & Alessandra Larocca. (2017) How is patient care for multiple myeloma advancing?. Expert Review of Hematology 10:6, pages 551-561.
Read now
Read now
Jean-Samuel Boudreault, Cyrille Touzeau & Philippe Moreau. (2017) The role of SLAMF7 in multiple myeloma: impact on therapy. Expert Review of Clinical Immunology 13:1, pages 67-75.
Read now
Read now
Katja Weisel. (2016) Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. OncoTargets and Therapy 9, pages 6037-6048.
Read now
Read now
Sebastian Grosicki & Agnieszka Barchnicka. (2016) Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma. Expert Review of Hematology 9:7, pages 621-628.
Read now
Read now
Articles from other publishers (21)
Lijun Yao, Julia T. Wang, Reyka G. Jayasinghe, Julie O'Neal, Chia-Feng Tsai, Michael P. Rettig, Yizhe Song, Ruiyang Liu, Yanyan Zhao, Omar M. Ibrahim, Mark A. Fiala, Julie M. Fortier, Siqi Chen, Leah Gehrs, Fernanda Martins Rodrigues, Michael C. Wendl, Daniel Kohnen, Andrew Shinkle, Song Cao, Steven M. Foltz, Daniel Cui Zhou, Erik Storrs, Matthew A. Wyczalkowski, Smrithi Mani, Scott R. Goldsmith, Ying Zhu, Mark Hamilton, Tao Liu, Feng Chen, Ravi Vij, Li Ding & John F. DiPersio. (2023) Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma. Cancer Research 83:8, pages 1214-1233.
Crossref
Crossref
Masahiro Yasunaga. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
31
.
Keke Fei, Haiqing Ni, Mengjia Zhu, Zhihui Kuang, Min Wu, Zhihai Wu, Feifei Wang, Shuaixiang Zhou, Hua Jing, Weiwei Wu, Dongdong Wu, Dongmei Bai & Bingliang Chen. (2022) IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. Cancer Letters 536, pages 215663.
Crossref
Crossref
Muhammed Iraqi, Avishay Edri, Yariv Greenshpan, Oron Goldstein, Noa Ofir, Priyanka Bolel, Muhammad Abu Ahmad, Miri Zektser, Kerry S. Campbell, Ory Rouvio, Roi Gazit & Angel Porgador. (2022) Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. International Journal of Molecular Sciences 23:9, pages 4717.
Crossref
Crossref
Constantine S. Mitsiades. (2021) Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. Cold Spring Harbor Perspectives in Medicine 11:7, pages a034900.
Crossref
Crossref
Tatsushi Kodama, Yu Kochi, Waka Nakai, Hideaki Mizuno, Takeshi Baba, Kiyoshi Habu, Noriaki Sawada, Hiroyuki Tsunoda, Takahiro Shima, Kohta Miyawaki, Yoshikane Kikushige, Yasuo Mori, Toshihiro Miyamoto, Takahiro Maeda & Koichi Akashi. (2019) Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics 18:9, pages 1555-1564.
Crossref
Crossref
John Shi, Juraj Bodo, Xiaoxian Zhao, Lisa Durkin, Tanu Goyal, Howard Meyerson & Eric D. Hsi. (2018) SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. British Journal of Haematology 185:1, pages 145-147.
Crossref
Crossref
Chutima Kunacheewa & Robert Z. Orlowski. (2019) New Drugs in Multiple Myeloma. Annual Review of Medicine 70:1, pages 521-547.
Crossref
Crossref
S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson & M Friedrich. (2016) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31:8, pages 1743-1751.
Crossref
Crossref
Charise Gleason & Donna D. Catamero. (2017) Immunotherapy in Multiple Myeloma. Seminars in Oncology Nursing 33:3, pages 292-298.
Crossref
Crossref
Noopur S. Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A. Holstein, Albert Oriol, Shang-Yi Huang, Meral Beksac, Kazimierz Kuliczkowski, Datchen F. Tai, James E. Wooldridge, Ilaria Conti, Christopher J. Kaiser, Tuan S. Nguyen, Damien M. Cronier & Antonio Palumbo. (2017) Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology 176:5, pages 783-795.
Crossref
Crossref
Yao Shen, Milda Stanislauskas, Gen Li, Deyou Zheng & Liang Liu. (2017) Epigenetic and genetic dissections of UV-induced global gene dysregulation in skin cells through multi-omics analyses. Scientific Reports 7:1.
Crossref
Crossref
Wilson I Gonsalves, Paolo Milani, Daniel Derudas & Francis K Buadi. (2017) The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncology 13:1, pages 63-75.
Crossref
Crossref
R. Ajina, D. AlDeghaither, S. Jablonski & L.M. Weiner. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
32
65
.
Robert Z. Orlowski & Sagar Lonial. (2016) Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clinical Cancer Research 22:22, pages 5443-5452.
Crossref
Crossref
J. Aubrey Waddell & Dominic A. SolimandoJrJr. (2016) Alectinib, Ceritinib, Elotuzumab, and Venetoclax. Hospital Pharmacy 51:7, pages 524-534.
Crossref
Crossref
Yu-Tzu TaiChirag AcharyaGang AnMichele MoschettaMike Y. ZhongXiaoyan FengMichele CeaAntonia CagnettaKenneth WenHans van Eenennaam, Andrea van Elsas, Lugui Qiu, Paul RichardsonNikhil MunshiKenneth C. Anderson. (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127:25, pages 3225-3236.
Crossref
Crossref
Tomas Jelinek & Roman Hajek. (2016) Monoclonal antibodies — A new era in the treatment of multiple myeloma. Blood Reviews 30:2, pages 101-110.
Crossref
Crossref
Ol'ga Mikhailovna Votyakova. (2016) Elotuzumab for Treatment of Multiple Myeloma (Literature Review). Clinical oncohematology 9:4, pages 438-445.
Crossref
Crossref
Russell Pachynski & Holbrook Kohrt. 2016. Novel Immunotherapeutic Approaches to the Treatment of Cancer. Novel Immunotherapeutic Approaches to the Treatment of Cancer
79
108
.
Antonio Palumbo. (2015) Immunotherapy: the next step in the treatment of myeloma. The Lancet Haematology 2:12, pages e504-e505.
Crossref
Crossref